Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC(+) tumors respond to PD1/PD-L1 blockade therapy

BACKGROUND: Insufficient co-stimulation accounts for a great deal of the suboptimal activation of cytotoxic CD8 T cells (CTLs) and presumably unsatisfactory clinical expectation of PD1/PD-L1 therapy. Tumor-derived soluble NKG2D ligands are associated with poor clinical response to PD1/PD-L1 blockade...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jinyu, Larrocha, Pablo Saenz-lopez, Zhang, Bin, Wainwright, Derek, Dhar, Payal, Wu, Jennifer D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709558/
https://www.ncbi.nlm.nih.gov/pubmed/31446896
http://dx.doi.org/10.1186/s40425-019-0693-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709558/
https://www.ncbi.nlm.nih.gov/pubmed/31446896
http://dx.doi.org/10.1186/s40425-019-0693-y

Ejemplares similares